Background {#Sec1}
==========

Over the past two decades there has been a considerable increase in the proportion of older patients commencing dialysis; yet there is some uncertainty about the outcome of dialysis in this population with respect to survival and also patients' health-related quality of life (HRQoL). There is currently minimal prospective data published on the key factors that might influence decision making or outcomes in the older age groups commencing renal replacement therapy. More recently, the SONG (Standardised Outcomes in NephroloGy) initiative has identified the importance of patient-reported outcome measures in studies of patients on dialysis \[[@CR1]\]. It is therefore important to identify those factors to inform shared decision making.

The Dialysis Outcomes in those aged 65 years or older study (DOS65) is an accelerated prospective cohort longitudinal study, designed to obtain sufficient HRQoL data, linked to clinical data, to inform clinicians' and patients' decision-making with respect to end stage kidney disease (ESKD) outcomes and options for management in New Zealand (NZ) \[[@CR2]\]. This study commenced in January 2010 and final follow up was completed in June 2016.

The focus of this paper is to describe the key characteristics of the study cohort at baseline, including the patients' health status, their treatment modality (not on dialysis, haemodialysis or peritoneal dialysis) and location of treatment (i.e. home or clinic/hospital facility). From the cross-sectional data at baseline, we hypothesise that HRQoL differs between patients according to: sex, ethnicity, comorbidities, type of dialysis treatment, health service satisfaction, and duration of dialysis.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The study has an accelerated prospective cohort longitudinal design, comprised of cross-sectional and longitudinal components (Fig. [1](#Fig1){ref-type="fig"}). The methods have been described previously \[[@CR2]\]. In particular, individuals who had a very limited life expectancy or significant active co-morbidity which was affecting their health were excluded by principal investigator at each site, as this would clearly impact on the perceived HRQoL questionnaires, but may not be attributable to dialysis and ESKD specifically. Recruitment was targeted to try and get at least one set of interviews at 12 months after enrolment for all participants where possible.Fig. 1Accelerated prospective cohort longitudinal design of the study, comprised of cross-sectional and longitudinal components with baseline recruitment numbers for participants over the 3 years of the study

Setting and participants {#Sec4}
------------------------

Eligible patients resided in one of three District Health Board (DHB) regions within NZ (Counties Manukau, Hawkes Bay or Southern) which reflect the diversity of the New Zealand population with Counties Manukau, a large urban population with high representation of Māori and Pacific people; Hawkes Bay, a regional farming centre which also has a high proportion of Māori and the Southern region with a predominantly European population spread over a large demographic area. All participants were 65 years or older, their clinical team considered them well enough to be approached to participate, and were either established on dialysis at the baseline interview or had a eGFR 15 ml/min 1.73 m^2^ or less and had commenced pre-dialysis education. In practice, this meant that some patients were already on dialysis for a number of years at the time of recruitment, whereas other patients had just commenced treatment. Clinicians from each DHB approached eligible patients and invited them to participate in the study. Ethical approval was granted by the New Zealand Health and Disability Ethics Committee (MEC/10/08/084) and the study is registered with Australian and New Zealand Clinical Trials Registry (ACTRN12611000024943).

Data collection {#Sec5}
---------------

Following consent, the patients were telephoned by a trained interviewer to arrange an interview either face to face or by telephone depending on the participants' preference. Interview questions were read aloud to participants, who were also provided with a printed sheet of response options to facilitate the interviews. The baseline interview was predominantly comprised of structured closed-response questions (see below).

Clinical data was collected at the same time as the first (baseline) interview for each participant. Clinicians completed a standardised clinical data abstraction form based on report forms used for the Dialysis Outcomes and Practice Patterns Study. Data collected included ethnicity, age, sex, co-morbidities, laboratory data, anthropometric measures, prescribed medications and details of renal replacement therapy \[[@CR3]\] In addition, we obtained aggregate data from routinely collected clinical and administrative hospital datasets included in the Australian and New Zealand Dialysis and Transplantation Registry (ANZDATA) to compare characteristics of our cohort with the broader New Zealand wide dialysis population in this age group \[[@CR4]\].

Variables {#Sec6}
---------

We collected socio-demographic characteristics using the same questions used in the 2009 New Zealand census: sex, age, relationship status, occupation, living arrangements and self-reported ethnicity \[[@CR5]\]. As participants were able to select multiple ethnicities, ethnicity was prioritised into Māori (New Zealand's indigenous population), Pacific peoples (Samoan, Tongan, Fijian, Cook Islander), other ethnicities (e.g. other European, Chinese, Indian) or New Zealand European \[[@CR5], [@CR6]\]. Socioeconomic data included home ownership \[[@CR5]\], whether income was solely dependent on Government Superannuation \[[@CR7]\], use of a means-tested community services card (to provide additional subsided health care) \[[@CR8]\], self-reported standard of living (responses: high, fairly high, medium, fairly low, low) \[[@CR9]\], adequacy of household income to meet every day needs (not enough, just enough, enough or more than enough), and education (the responses were merged into 3 categories: none, secondary (age 12--18 years), post-secondary) \[[@CR9]\].

The New Zealand Deprivation Index (NZDep2006) is calculated for small New Zealand geographical areas using 9 dimensions of socio-economic disadvantage to create a summary score to estimate socioeconomic status using data collected in Statistics New Zealand's 2006 Census of Population and Dwellings \[[@CR10]\]. The higher the number (range 1--10) the greater the estimated socioeconomic deprivation.

General health status was assessed using the EQ-5D-3 L \[[@CR11]\], as previously used in studies of Chronic Kidney Disease (CKD) populations \[[@CR11], [@CR12]\]. The Kidney Disease Quality of Life - 36 (KDQoL-36) was used to assess the functioning and well-being of people with CKD \[[@CR12]--[@CR14]\].

We collected responses to the Functional Assessment of Chronic Illness Therapy (FACIT) survey, which is a collection of health-related quality of life measures targeted to the management of chronic disease and has been validated in elderly populations \[[@CR15]\]. The higher the score the higher the level of satisfaction with health care. A total FACIT score was calculated as a simple (unweighted) sum of all the subscale scores, rescaled to a 0 to 100 scale. This was calculated only for people with valid sub-scales for all dimensions.

The level of disability for participants was measured using the WHODAS II 12-item measure which assesses activity limitations and participation over the past 30 days using a five point Likert scale ("none/mild/moderate/extreme/cannot do") for each item. \[[@CR16]\] A WHODAS disability score was derived using the summed approach (where 0 = no disability and 48 = disability). When one WHODAS item was missing, the individual's average was imputed; when more items were missing, the disability score was not derived. \[[@CR16]\]

Well-being was measured using the Personal Wellbeing Index \[[@CR17]\]. This scale is an eight-item measure assessing the level of satisfaction with; standard of living, health, achieving in life, relationships, safety, community connectedness, future security and spirituality or religion. Respondents rated their satisfaction on an 11 point scale (0 completely dissatisfied to 10 completely satisfied). Scores for individuals were derived as an average across all items and converted to a zero to 100 scale.

Data analysis {#Sec7}
-------------

Data analysis was conducted Stata® 13.1 software (StataCorp. 2013. *Stata Statistical Software: Release 13*. College Station, TX, USA. Descriptive statistics were calculated. ANOVA (for continuous data) and Chi Square (for categorical data) were used to compare groups (e.g. non-responders versus responders).

Results {#Sec8}
=======

Participants {#Sec9}
------------

Between 1 January 2010 and 31 March 2014 there were 388 potential participants of whom 56 were ineligible for the first interview because; they died before interview was scheduled (*n* = 11) or a clinician advised interview would be inappropriate given the poor health status of the patient or anticipated limited life expectancy (*n* = 45). Of the 332 potential participants, 107 (32%) declined to participate in the study, leaving 225 (68%) participants (Figs. [1](#Fig1){ref-type="fig"} & [2](#Fig2){ref-type="fig"}). The demographic characteristics of patients who agreed and declined to participate in the study is provided in Table [1](#Tab1){ref-type="table"}. There were a number of statistically significant differences between the two groups. Participants were more likely to be male, of European ethnicity and on dialysis. Over half of the 225 participants (54%) completed a face to face interview, 45% by telephone and 1 completed a postal questionnaire. Interviews took on average one hour to complete. 25 participants (11%) had limited or no English language ability and were assisted by a bi-lingual translator.Fig. 2Flow-chart demonstrating recruitment for the studyTable 1Comparison of participants and non-participantsParticipated (*N* = 225)Declined to participate (*N* = 107)chi^2^ *p* valuen%n%Gender Male14464.04945.8 Female8136.05854.20.002Age group 65--698738.75046.7 70--746428.43633.6 75--794520.01211.20.097 80+2912.998.4 median age71--70--Ethnicity (as in ANZDATA) European10848.01110.3 Māori4520.02422.4 Pacific5323.65248.60.000 Other198.41917.8 Missing00.010.9Ethnicity (Self reported multiple ethnicities were prioritised) Europeans9642.7-- Māori5022.2 Pacific5223.1-- Other2712.0Receiving dialysis Yes16975.16863.6 No5624.93936.40.029Living Arrangement Alone3314.7---- Living with others19285.3Cigarette smoking Current smoker146.2-- Ex smoker11852.4 Never smoker9140.4-- Missing20.9Alcohol drinker Current drinker9642.7---- Non drinker12957.3Highest educational qualification None10848.0-- Secondary (age 13--18)4419.6 Post secondary6930.7-- Missing41.8Comorbidities^a^ Cardiovascular disease15167.16863.60.52 Cerebrovascular disease177.643.70.18 Peripheral vascular disease4520.02119.60.94 Diabetes mellitus12053.38074.8\< 0.01 Respiratory disease4921.81211.20.02 Cancer (other than skin cancer)3816.987.50.02 Musculoskeletal6830.23229.90.95 Other14062.28175.70.02Comorbidity count 0 to 210446.24037.4 3 to 612153.86762.60.13Cause of ESKD Glomerulonephritis3816.91514.0 Hypertension3816.9109.3 Polycystic kidney125.300.0\< 0.01 Diabetes mellitus9240.96863.6 Other4520.01413.1^a^multiple comorbidities possible

A comparison of DOS65's population with the entire comparative age group on dialysis in NZ \[[@CR4]\], found there was no significant difference in the distribution according to age or sex. In DOS65, 42% were dialysing at home which reflects national trends \[[@CR4]\]. When compared to the New Zealand wide dialysis population of the same age \[[@CR4]\], DOS65 had a higher proportion of Pacific participants (23% vs 17%), a similar proportion of Māori participants (22% vs 25%) and a slightly lower proportion of New Zealand Europeans (43% vs 49%). When compared to the general NZ population over the age of 65, Māori (22% vs 5%) and Pacific people (23% vs 2%) were over represented in the study population \[[@CR9]\].

Participant characteristics are summarised in Table [1](#Tab1){ref-type="table"}. Nearly two thirds of the study cohort were male and the median age at interview was 71 years (interquartile range, IQR 68 to 76 years). Three quarters (*n* = 169) of the patients were receiving dialysis (109 haemodialysis and 60 peritoneal dialysis). Of those on dialysis, 70 (41%) were dialysing at home; and 99 (59%) underwent centre-based haemodialysis. 119 (70%) had been dialysing for more than one year at baseline; 57 (34%) had been dialysing for between 1 and 3 years and 62 (37%) had been dialysing for more than 3 years. Fifty (30%) were incident dialysis patients (started dialysis within the past 12 months). Of the 56 non-dialysis patients, 9 had elected for conservative treatment (i.e. had made a conscious choice to not go onto dialysis), and 47 were defined as pre-dialysis. There was no sub-cohort effect observed across dialysis duration (Table [2](#Tab2){ref-type="table"}). Of the pre-dialysis patients, 5 had been deemed medically unfit to start dialysis, 41 had chosen to dialyse but had not reached the point at which dialysis needed to be started, and 1 patient had not yet made up his/her mind about whether to dialyse or not.Table 2Assessing possibility of subcohort effect in accelerated prospective designPredialysis (*n* = 56)Incident (\< 1 year) (*n* = 50)Prevalent (1--3 years) (*n* = 57)Prevalent (\>  3 years) (*n* = 62)*p* valuen%n%n%n%Gender Male3766.13366.03561.43962.9 Female1933.91734.02238.62337.10.94Age group 65--692035.72040.02136.82641.9 70--741119.61632.01526.32235.5 75--791323.2612.01628.11016.10.13 80+1221.4816.058.846.5Ethnicity (self reported) European3053.61938.02340.42438.7 Māori1017.91020.01831.61219.4 Pacific610.71734.01017.51930.60.06 Other1017.948.0610.5711.3Comorbidities^a^ Cardiovascular disease3664.33366.03866.74471.00.88 Cerebrovascular disease47.136.058.858.10.97 Peripheral vascular disease1323.2714.01119.31422.60.63 Diabetes mellitus2748.22958.03256.13251.60.74 Respiratory disease1628.61020.0915.81422.60.43 cancer (other than skin cancer)814.31122.0814.01117.70.67 Musculoskeletal1832.11428.01424.62235.50.60 Other3664.33060.03764.93759.70.91Comorbidity count 0 to 22442.92346.02950.92845.2 3 to 63257.12754.02849.13454.80.85Cause of ESKD Glomerulonephritis814.3918.0712.31422.6 Hypertension1017.9714.01221.1914.5 Polycystic kidney23.612.047.058.1 Diabetes mellitus2035.72244.02747.42337.10.55 Other1628.61122.0712.31117.7^a^multiple comorbidities possible

Diabetes mellitus was the most common cause of ESKD (41%) followed by glomerulonephritis (17%) and hypertensive disease (17%). The majority of participants had 3 or more comorbidities, of which cardiovascular disease (CVD) (67%), followed by diabetes mellitus (53%) were the most common. The number of comorbidities ranged from zero to 6 with a median of 3 (IQR 2 to 4) (Table [1](#Tab1){ref-type="table"}). Over half the population had previously smoked (52%) though there were very few current smokers (6%). The population was less well educated than the general NZ population of the same age with 48% of the study population not having achieved a secondary school education as compared with 39% of the NZ population over the age of 65 (2013 NZ Census). The study population lived in more deprived areas than the general NZ population over the age of 65. DOS65 participants were poorer socioeconomically, according to the NZDep, than the general population (6.9 and 5.4 respectively, *p* \< 0.01), and more than half (54%) lived in areas classified as having the poorest three deciles. (Personal communication Dr. June Atkinson Department of Public Health, University of Otago Wellington, NZ; data sourced from Statistics New Zealand).

Table [3](#Tab3){ref-type="table"} describes participants' sociodemographic characteristics by baseline renal replacement therapy, dialysis duration and location of treatment. The length of time on dialysis (dialysis vintage) did not vary by gender, age, ethnicity, distance from dialysis facility or any makers of socioeconomic status. In contrast dialysis modality and location was highly associated with socio-demographic factors. Female participants were less likely to dialyse at home than males (27 vs 49%). When compared to the NZ European population a smaller proportion of Māori (25 vs 61%) or Pacific people (24vs 61%) dialysed at home. Participants living further away from the dialysis centre were more likely to undertake a home therapy, particularly peritoneal dialysis. Patients dialysing in-centre (compared to those dialysing at home), were more likely to be socioeconomically disadvantaged as indicated by not owning their own home (72 vs 48%), being more likely to have a community services card (85%vs 62%), reporting a low/very low standard of living (14% vs 3%) and living in a more deprived NZDep area (mean 7.6 vs 6.1). Age had no impact on dialysis location and people living alone were no less likely to undertake a home therapy. Patients dialysing at home had a similar number of comorbidities to those dialysing in-centre. The characteristics of the pre-dialysis population was similar to the population on peritoneal dialysis. Females, Māori and Pacific people, those who lived closer to a dialysis centre, and those who were socioeconomically poorer, were more likely to undertake haemodialysis when compared to the peritoneal dialysis or predialysis population.Table 3Sociodemographic characteristics of study cohort by type of treatment, location and time on treatmentNot on dialysis (N = 56)Type of dialysisDialysis Location\*\*Time on dialysis\*\*CharacteristicHaemodialysis (*n* = 109)Peritoneal (*n* = 60)*p value \**Home (*n* = 70)In centre (*n* = 99)*p value \**Incident (\< 1 year) (n = 50)Prevalent (1--3 years) (n = 57)Prevalent (\>  3 years) (n = 62)*p value \**Gender Male376344*0.045*5354*0.005*333539*0.883* Female1946161745172223Age group 65--692043242938202126 70--74113518*0.729*2231*0.808*161522*0.262* 75--79132210112161610  ≥ 80129889854Prioritised ethnicity European3032344026192324 Māori10319*0.005*1030*0.000*101812*0.457* Pacific635111135171019 Other1011698467Distance in km to dialysis centre Less than 103065272963283133 10--49193923*0.019*2636*0.000*162323*0.739* 50+7510150636Lifestyle behaviour Current smoker473*0.708*46*1.000*226*0.287* Currently drinks alcohol303927*0.240*3828*0.001*192225*0.965* Lives alone16107*0.606*710*1.000*269*0.182*Own home Yes375743*0.040*5149*0.008*313534*0.505* No1951171949182228 Missing01001100Pension is the only source of income Yes358040*0.309*4575*0.083*324444*0.400* No2128202523171318 Missing01001100Have a community services card? Yes438542*0.505*4483*0.007*344449*0.210* No1323172515141313 Missing01111200Standard of living Fairly Low/Low4152*0.033*314*0.034*557*0.901* High/fairly high/medium5293586784445255 Missing01001100Adequacy of income for daily needs Enough/More than enough275026*0.712*3145*0.834*213025*0.373* Not enough/Just enough2958343953282737 Missing01001100Qualifications265626*0.217*3151*0.233*242731*0.850* None3049343944253028 Secondary school/higher/trade qualification04004103 MissingComorbidity Count 0--2245228*0.900*3248*0.722*232928*0.802* 3+3257323851272834NZDep score (mean & SD)6.6(2.9)7.3(2.8)6.2(3.1)0.0166.1(2.9)7.6(2.8)0.0017.0(3.1)6.9(2.9)6.9(2.9)0.98\**P* values are from chi-square test except for NZDep score where *P* values are from ANOVA. Non-dialysis group now excluded from test when comparing dialysis types, \*\* 8 people are in 'in training' for dialysis. Two of them were included in "home" group as they are training at home, other 6 were included in "centre" group

Table [4](#Tab4){ref-type="table"} presents self-reported HR-QOL, disability and personal well-being measures at baseline. With the exception of dialysis location on EQ-5D-3 L VAS, these self-reported scales of health and disability were not impacted by being on dialysis or by dialysis modality, location or duration.Table 4Health and disability measures by type of treatment, location and time on treatmentNot on dialysis (N = 56)Type of dialysisLocationTime on dialysisCharacteristicHaemodialysis (n = 109)Peritoneal (n = 60)*p value \**Home (n = 70)In centre (n = 99)*p value \**Incident (\< 1 year) (n = 50)Prevalent (1--3 years) (n = 57)Prevalent (\>  3 years) (n = 62)*p value \**EQ5D_VAS Health state today(median & IQR)70\
(50 to 80)70\
(60 to 80)67.5\
(50 to 80)0.5462.5\
(50 to 80)70\
(60 to 80)0.0167.5\
(50 to 80)70\
(60 to 80)70\
(50 to 80)0.49FACIT total score (median & IQR91.4\
(83.9 to 96.6)90.5\
(78.2 to 95.3)90.2\
(84.7 to 96.0)0.9090.1\
(83.6 to 95.9)91.2\
(78.2 to 95.8)0.6485.7\
(74.5 to 95.9)90.1\
(83.0 to 95.0)91.7\
(82.4 to 96.3)0.09Personal Wellbeing Index total score (median & IQR)76.9\
(66.3 to 87.5)78.8\
(68.8 to 87.5)76.3\
(62.5 to 83.8)0.4576.3\
(62.5 to 83.8)80\
(68.9 to 87.5)0.2379.4\
(65.0 to 85.6)75.0\
(65.0 to 83.8)78.8\
(70.0 to 87.5)0.49WHODAS score (median & IQR).10.0\
(5.0 to 15.0)11.0\
(6.0 to 17.5)11.5\
(5.0 to 19.0)0.7310.5\
(5.0 to 19.0)11.0\
(6.0 to 18.0)0.7311.0\
(5.0 to 17.0)11.5\
(8.0 to 16.0)11.5\
(5.0 to 19.0)0.88Kidney symptom score (Median & IQR)78.4\
(62.5 to 88.6)81.3\
(66.6 to 87.5)77.1\
(62.5 to 87.5)0.1579.2\
(64.6 to 87.5)81.3\
(66.7 to 89.6)0.5379.2\
(60.4 to 85.4)81.3\
(64.6 to 87.5)81.3\
(68.8 to 89.6)0.87There were no missing values for EQ5D_VAS or the Kidney symptom score, 2 participants had missing WHODAS values, 21 participants had missing FACIT values (16 in the non dialysis group) and 29 participants had missing values from the Personal Wellbeing Index

Discussion {#Sec10}
==========

The DOS65 study is an accelerated prospective cohort longitudinal design study over 3 years, designed to obtain HRQoL data, which when linked to clinical data, will help inform clinicians' and patients' shared decision-making with respect to end stage kidney disease (ESKD), outcomes and options for management in New Zealand (NZ) \[[@CR2]\]. The outcomes of this study align well with the SONG initiative, and the importance of reporting patient-related outcomes \[[@CR1]\]. This paper reports the baseline characteristics of the study cohort.

Patients who participated in the study were more likely (than those who declined to participate) to be male, of NZ European descent and on dialysis treatment. However, despite this, by selecting 3 different regions with differing population characteristics, we achieved a reasonable representation of the NZ dialysis population in this age group. Given the much higher incidence and prevalence of ESKD (3.5--5.5 fold) \[[@CR18]\] and CKD \[[@CR19]\] among Māori and Pacific populations, and differences in outcome measures and HRQoL by ethnicity \[[@CR20]--[@CR23]\], it was essential that good representation of these populations was achieved.

While diabetes mellitus was the most common cause of ESKD this was less prevalent than in the general NZ dialysis population \[[@CR4]\]. As one would expect, this is a highly comorbid population. When compared to the DOPPS population over 65, comorbidity rates were broadly similar \[[@CR24]\], with more than half the study populations having cardiac disease. This population had a higher rate of diabetes mellitus but lower rates of cerebrovascular and peripheral vascular disease. The increased prevalence of diabetes mellitus reflects the participation of Māori and Pacific people with well documented increased propensity to ESKD as a result of diabetes mellitus \[[@CR18]\].

In the general population socioeconomic deprivation plays an important role in the development and progression of kidney disease, and conversely, chronic kidney disease may result in socioeconomic deprivation \[[@CR20], [@CR25], [@CR26]\]. Study participants were much more likely to live in a more deprived area, were less well educated, and were financially less well off than other New Zealanders of a similar age. While the association of socioeconomic disadvantage and renal replacement therapy is well established in the general population, Australian data has previously suggested that this is less relevant in older dialysis patients \[[@CR27]\]. To our knowledge this is the first cohort to describe an association between socioeconomic disadvantage and renal replacement therapy in this population. The main factor influencing where participants resided and hence deprivation index was ethnicity. Māori and Pacific people were much more likely to live in the two most socioeconomically deprived deciles with 68% of Māori and 81% of Pacific participants living in decile 9 or 10 areas as opposed to 13% of NZ Europeans.

New Zealand has among the highest rates of home-based dialysis internationally, even among older age groups. \[[@CR4]\]. In this cohort, 42% were dialysing at home which reflects the national trend \[[@CR4]\]. Most patients dialysing at home were on PD, with only 10 participants on home HD. We found that patients dialysing at home were more likely to own their own home, more likely to have more than one source of income, less likely to have a community services card, and lived in less deprived areas but interestingly were just as likely to report inadequate or barely adequate financial resources. Those patients on home dialysis were also more likely to be male, be of NZ European descent and to live further from the dialysis centre. The pre-dialysis population was similar to the peritoneal dialysis population with similar apparent socioeconomic advantage over the in-centre dialysis population. While the population undertaking in-centre haemodialysis was different than the home or pre-dialysis population, dialysis vintage was associated with no significant demographic differences.

Despite the differences in socioeconomic status, multiple measures of health and disability status did not vary by being on dialysis, by dialysis modality, dialysis location of time on renal replacement therapy. This would imply that factors outside of socioeconomic status have more influence on these characteristics.

Strengths of this study are that we achieved good representation of the NZ dialysis population over the age of 65. Importantly, participation of Māori and Pacific people were at rates higher, or equivalent to, rates of renal replacement therapy in these ethnic groups. Comorbidity data was individually collected from patient hospital records. Multiple measures of socioeconomic status were collected either directly from the participant or from national census data. Prioritised ethnicity data was collected directly from the participant which has been shown to be more reliable than electronic health records \[[@CR6]\]. Multiple measures of health status, HRQoL, disability and personal well-being were recorded by trained interviewers.

In NZ dialysis is entirely provided within the publicly- funded health system and therefore decisions related to acceptance onto dialysis, the modality of dialysis, and subsequent participation in this study, is not subject to participant insurance status or other financial factors.

While those who participated were representative of the NZ wide dialysis population of a similar age, females, Māori and Pacific people and those not on dialysis were less likely to participate. In particular, a relatively low number of Māori and Pacific who were either undertaking peritoneal dialysis or who were pre-dialysis participated. This may limit the generalisability of findings for these populations, though as a prospective cohort study, participation bias has little concern when looking at risk factors for outcomes of interest that have not yet occurred.

Our future analyses will concentrate on characterizing the evolution of patient-related over time. Our study has an accelerated longitudinal design, which is similar to that used in the Dialysis Outcomes and Practice Patterns Study, where analyses are also made on a mix of incident and prevalent dialysis patients \[[@CR3]\]. The difference is that in the DOPPS, most analyses are performed using time-to-event models for outcomes such as mortality. As such, patients are "lined up" at their time of study entry, controlling for vintage (on a continuous scale) by including it in a model. In our study, most analyses will be observations of patient-related outcomes at various follow-up points post-dialysis inception. As such, patients will be "lined up" by vintage. For these sorts of outcomes, there is no difference between the accelerated longitudinal design used in our study versus that which using an incident or inception cohort design -- in our study, prevalent patients recruited at year 2 post-dialysis inception followed for two years with have the same cross-sectional characteristics at each landmark as incident patients recruited at dialysis inception followed for four years. In both cases, there is no issue with survival bias; for instance, one can only compare HRQoL at a landmark in patients who have survived to that point, and no other analytical framework makes clinical sense. Table [2](#Tab2){ref-type="table"} demonstrates that patients can be pooled without any sub-cohort effect related the sampling frame.

In the case that we analyse follow-up data using time-to-event models, for instance to assess mortality, we will use similar methods to the DOPPS \[[@CR3]\] with left truncation (at time of study entry) in to account for the potential bias of missing patients who did not make it to the point of study entry. In such analyses, survival time is conditional on having already survived from the point of risk (dialysis inception) to first coming under observation (study entry). In New Zealand, less than 2% of the dialysis population aged 65 or older receive a renal transplant (4), and the competing risk of transplant will not be a factor in analysing outcomes in this study.

Conclusions {#Sec11}
===========

In summary, we report the baseline characteristics of participants enrolled prospectively into a longitudinal cohort observation study examining HRQoL factors with clinical characteristics on dialysis outcomes in a group of New Zealand aged 65 years or older who are either on dialysis or have been educated about dialysis \[[@CR2]\]. In combination with our protocol paper \[[@CR2]\], this paper allows readers a clear understanding of the participants enrolled in the study, in order to compare with their own clinical practice. Subsequent publications are planned, analysing the prospective longitudinal data to identify key factors that determine both outcome and quality of life for individuals of this age group.
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